Clinical Trial Intelligence monitors every active trial across all sites simultaneously — something impossible for a human team across 47 concurrent studies. Protocol adherence: every patient visit, every data point, and every adverse event is checked against the protocol in real time. Deviation detected within hours, not at the next monitor visit. Patient recruitment: AI matches eligible patients from EHR data, genomic databases, and patient registries — increasing recruitment rate 34% and reducing screen failure rate by 28%. Site performance: underperforming sites identified 6 weeks before they impact timeline. Supply chain: investigational product supply to each site tracked and reordered automatically. All protocol decisions require Principal Investigator approval.

Regulatory Intelligence monitors guidance documents, draft regulations, and agency communications from FDA, EMA, PMDA, ANVISA, and 12 other agencies simultaneously — alerting regulatory affairs teams to changes relevant to their programmes within 24 hours of publication. Submission preparation: AI extracts structured content from study reports, formats to CTD structure, cross-references against agency guidance, and flags gaps before submission. Common Technical Document compilation: what previously took 6 months of manual effort is reduced to weeks. All regulatory strategy decisions and submission content require Regulatory Affairs director review and sign-off. AI prepares — humans approve and submit.

Drug Discovery AI scans 2.4M compounds across proprietary databases, published literature, patent filings, and clinical data to identify promising candidates and predict ADMET properties (Absorption, Distribution, Metabolism, Excretion, Toxicity) before wet lab work begins. Target identification: protein interaction networks and disease pathway analysis surface novel targets from genomic and proteomic data. Literature intelligence: 50,000+ papers processed weekly — key findings, competitive intelligence, and mechanistic insights extracted and summarised for scientists. All candidate selection decisions remain with medicinal chemists and discovery leadership.